指南与共识乳腺癌

患者与疾病因素在早期可手术乳腺癌辅助全身治疗决策中的作用:ASCO对Cancer Care Ontario指南推荐的更新

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
指南 / 共识 · J Clin Oncol · 2019-06-17

美国临床肿瘤学会(ASCO)更新对Cancer Care Ontario关于早期可手术乳腺癌辅助全身治疗决策中患者与疾病因素作用的推荐。基于TAILORx和MINDACT两项III期试验证据,更新了Oncotype DX复发评分指导化疗决策的推荐,并明确了MammaPrint检测的适用人群。

要点

  • 对于年龄>50岁且Oncotype DX复发评分<26,或年龄≤50岁且评分<16的患者,化疗获益甚微或无,可单用内分泌治疗。
  • 对于年龄≤50岁且复发评分16-25的患者,可考虑化疗联合内分泌治疗;评分>30应考虑化疗联合内分泌治疗。
  • MammaPrint检测可用于指导激素受体阳性、淋巴结阴性及选择性淋巴结阳性患者是否省略辅助化疗,但仅在高临床风险患者中显示临床效用。

核心结论

  • 对于年龄>50岁且Oncotype DX复发评分<26,或年龄≤50岁且评分<16的激素受体阳性、淋巴结阴性乳腺癌患者,化疗获益甚微或无,可单用内分泌治疗。
  • 对于年龄≤50岁且复发评分16-25的患者,可考虑化疗联合内分泌治疗;评分>30的患者应考虑为化疗联合内分泌治疗的候选者。
  • 基于非正式共识,专家组推荐肿瘤内科医生可对Oncotype DX评分26-30的患者提供化疗联合内分泌治疗。
  • MammaPrint检测可用于指导激素受体阳性、淋巴结阴性及选择性淋巴结阳性乳腺癌患者是否省略辅助全身化疗。
  • 在淋巴结阳性和阴性患者中,MammaPrint检测的临床效用证据仅在高临床风险患者中显现,专家组因此不推荐在低临床风险患者中使用MammaPrint检测。

研究设计与样本

  • 本更新基于两项III期试验:TAILORx试验(入组激素受体阳性、淋巴结阴性肿瘤女性)和MINDACT试验(入组淋巴结阴性及1-3枚阳性淋巴结疾病患者)。
  • 由ASCO专家组对Cancer Care Ontario推荐进行更新认可。

主要发现

  • TAILORx和MINDACT两项III期试验为本次更新提供了证据。
  • 对于年龄>50岁且Oncotype DX复发评分<26,以及年龄≤50岁且评分<16的患者,化疗获益甚微或无。
  • 对于年龄≤50岁且复发评分16-25的患者,可提供化疗联合内分泌治疗。
  • 复发评分>30的患者应考虑为化疗联合内分泌治疗的候选者。
  • MammaPrint检测的临床效用证据仅在淋巴结阳性和阴性患者中确定为高临床风险者中显现。

关键数值与推荐

  • 年龄>50岁且Oncotype DX复发评分<26:化疗获益甚微或无,可单用内分泌治疗。
  • 年龄≤50岁且Oncotype DX复发评分<16:化疗获益甚微或无,可单用内分泌治疗。
  • 年龄≤50岁且Oncotype DX复发评分16-25:可提供化疗联合内分泌治疗。
  • Oncotype DX复发评分>30:应考虑为化疗联合内分泌治疗的候选者。
  • 基于非正式共识,专家组推荐肿瘤内科医生可对Oncotype DX评分26-30的患者提供化疗联合内分泌治疗。

临床怎么用

  • 临床医生与患者之间的共享决策适用于乳腺癌辅助全身治疗。
  • 对于年龄>50岁且Oncotype DX评分<26,或年龄≤50岁且评分<16的患者,临床医生可单用内分泌治疗。
  • 对于年龄≤50岁且评分16-25的患者,临床医生可提供化疗联合内分泌治疗。
  • 肿瘤内科医生可对Oncotype DX评分26-30的患者提供化疗联合内分泌治疗(基于非正式共识的专家组推荐)。
  • MammaPrint检测可用于指导激素受体阳性、淋巴结阴性及选择性淋巴结阳性乳腺癌患者是否省略辅助全身化疗;不推荐在低临床风险患者中使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To update the American Society of Clinical Oncology endorsement of the Cancer Care Ontario recommendations on the Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer. METHODS: Two phase III trials-the Trial Assigning Individualized Options for Treatment (TAILORx) in women with hormone receptor-positive, node-negative tumors and the Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) trial-provided the evidence for this update. UPDATED RECOMMENDATIONS: Shared decision making between clinicians and patients is appropriate for adjuvant systemic therapy for breast cancer. For patients older than age 50 years and whose tumors have Oncotype DX recurrence scores less than 26, and for patients age 50 years or younger whose tumors have Oncotype DX recurrence scores less than 16, there is little to no benefit from chemotherapy. Clinicians may offer endocrine therapy alone for these patients. For patients age 50 years or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the Panel recommends that oncologists may offer chemoendocrine therapy to patients with Oncotype DX scores of 26 to 30.The MammaPrint assay could be used to guide decisions on withholding adjuvant systemic chemotherapy in patients with hormone receptor-positive lymph node-negative breast cancer and in select patients with lymph node-positive cancers. In both patients with node-positive and node-negative disease, evidence of clinical utility of the MammaPrint assay was only apparent in those determined to be at high clinical risk; the Panel thus did not recommend use of MammaPrint assay in patients determined to be at low clinical risk. Remaining recommendations from the 2016 ASCO guideline endorsement are unchanged.Additional information is available at www.asco.org/breast-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Henry NL, Somerfield MR, Abramson VG, et al. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline. J Clin Oncol. 2019. PMID: 31206315. doi:10.1200/JCO.19.00948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。